Bromocriptine formulations
The present disclosure describes pharmaceutical formulations of bromocriptine and methods of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.
1. A pharmaceutical formulation comprising bromocriptine citrate in an amount that provides a dose of between 0.1 and 9.6 mg. bromocriptine, and excipients; wherein the excipients comprises 0.1-10% of a triglyceride, 30-90% mannitol, and 0.1-10% citric acid, and wherein the pharmaceutical formulation is substantially free of magnesium or lactose.
2. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is free of magnesium or lactose.
3. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation comprises a tablet or oral dosage form.
4. The pharmaceutical formulation of claim 1 , wherein the triglyceride comprises solid castor oil.
5. The pharmaceutical formulation of claim 1 wherein the bromocriptine citrate is more stable in an aqueous environment than bromocriptine mesylate.
6. The pharmaceutical formulation of claim 1 wherein the bromocriptine citrate is soluble in water to at least 500 mg/L at 20° C.
7. The pharmaceutical formulation of claim 3 comprising a parenteral dosage form.
8. The pharmaceutical dosage form of claim 3 comprising a sublingual dosage form.
9. The pharmaceutical dosage form of claim 7 having a pharmacokinetic profile with a plasma T max from about 1 to about 90 minutes after administration, and a plasma drug concentration of at least 50% c max for a duration of about 90 to about 360 minutes.
10. The pharmaceutical formulation of claim 7 wherein the bromocriptine is micronized.
11. A pharmaceutical formulation comprising 0.1-9.6 mg. bromocriptine citrate and excipients; wherein the excipients comprise 0.1-10% hydrogenated castor oil, 30-90% mannitol, and 0.1-10% citric acid, the pharmaceutical formulation is free of magnesium or lactose, and the bromocriptine is micronized and has a Dv90 of about 10 μm or lower.
12. The pharmaceutical formulation of claim 1 wherein the bromocriptine is micronized.